Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

A bridge between academic and community radiation oncology treatment planning.

Maguire PD, Honaker G, Neal C, Meyerson M, Morris D, Rosenman J, Tepper J.

J Oncol Pract. 2007 Sep;3(5):238-41. doi: 10.1200/JOP.0752001.

2.

Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.

Jackman DM, Yeap BY, Lindeman NI, Fidias P, Rabin MS, Temel J, Skarin AT, Meyerson M, Holmes AJ, Borras AM, Freidlin B, Ostler PA, Lucca J, Lynch TJ, Johnson BE, Jänne PA.

J Clin Oncol. 2007 Mar 1;25(7):760-6. Epub 2007 Jan 16.

PMID:
17228019
3.

Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors.

Thomas RK, Greulich H, Yuza Y, Lee JC, Tengs T, Feng W, Chen TH, Nickerson E, Simons J, Egholm M, Rothberg JM, Sellers WR, Meyerson ML.

Cold Spring Harb Symp Quant Biol. 2005;70:73-81.

PMID:
16869740
4.

"Lineage addiction" in human cancer: lessons from integrated genomics.

Garraway LA, Weir BA, Zhao X, Widlund H, Beroukhim R, Berger A, Rimm D, Rubin MA, Fisher DE, Meyerson ML, Sellers WR.

Cold Spring Harb Symp Quant Biol. 2005;70:25-34.

PMID:
16869735
5.

Allele-specific amplification in cancer revealed by SNP array analysis.

LaFramboise T, Weir BA, Zhao X, Beroukhim R, Li C, Harrington D, Sellers WR, Meyerson M.

PLoS Comput Biol. 2005 Nov;1(6):e65. Epub 2005 Nov 25.

6.

The menin tumor suppressor protein is an essential oncogenic cofactor for MLL-associated leukemogenesis.

Yokoyama A, Somervaille TC, Smith KS, Rozenblatt-Rosen O, Meyerson M, Cleary ML.

Cell. 2005 Oct 21;123(2):207-18.

7.
8.

Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c.

Karnik SK, Hughes CM, Gu X, Rozenblatt-Rosen O, McLean GW, Xiong Y, Meyerson M, Kim SK.

Proc Natl Acad Sci U S A. 2005 Oct 11;102(41):14659-64. Epub 2005 Sep 29.

9.

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.

Greulich H, Chen TH, Feng W, Jänne PA, Alvarez JV, Zappaterra M, Bulmer SE, Frank DA, Hahn WC, Sellers WR, Meyerson M.

PLoS Med. 2005 Nov;2(11):e313. Epub 2005 Oct 4.

10.

An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.

Kobayashi S, Ji H, Yuza Y, Meyerson M, Wong KK, Tenen DG, Halmos B.

Cancer Res. 2005 Aug 15;65(16):7096-101.

11.

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma.

Garraway LA, Widlund HR, Rubin MA, Getz G, Berger AJ, Ramaswamy S, Beroukhim R, Milner DA, Granter SR, Du J, Lee C, Wagner SN, Li C, Golub TR, Rimm DL, Meyerson ML, Fisher DE, Sellers WR.

Nature. 2005 Jul 7;436(7047):117-22.

12.

Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis.

Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, Garraway L, Beheshti J, Lee JC, Naoki K, Richards WG, Sugarbaker D, Chen F, Rubin MA, Jänne PA, Girard L, Minna J, Christiani D, Li C, Sellers WR, Meyerson M.

Cancer Res. 2005 Jul 1;65(13):5561-70.

13.

Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy.

Meyerson M, Carbone D.

J Clin Oncol. 2005 May 10;23(14):3219-26. Review.

PMID:
15886309
14.

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Fröhling S, Döhner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG.

Cancer Cell. 2005 Apr;7(4):387-97.

15.

EGFR gene mutations: a call for global x global views of cancer.

Sellers WR, Meyerson M.

J Natl Cancer Inst. 2005 Mar 2;97(5):326-8. No abstract available.

PMID:
15741561
16.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B.

N Engl J Med. 2005 Feb 24;352(8):786-92.

17.

Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays.

Dobbin KK, Beer DG, Meyerson M, Yeatman TJ, Gerald WL, Jacobson JW, Conley B, Buetow KH, Heiskanen M, Simon RM, Minna JD, Girard L, Misek DE, Taylor JM, Hanash S, Naoki K, Hayes DN, Ladd-Acosta C, Enkemann SA, Viale A, Giordano TJ.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):565-72.

18.

Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors.

Milne TA, Hughes CM, Lloyd R, Yang Z, Rozenblatt-Rosen O, Dou Y, Schnepp RW, Krankel C, Livolsi VA, Gibbs D, Hua X, Roeder RG, Meyerson M, Hess JL.

Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):749-54. Epub 2005 Jan 7.

19.

The parafibromin tumor suppressor protein is part of a human Paf1 complex.

Rozenblatt-Rosen O, Hughes CM, Nannepaga SJ, Shanmugam KS, Copeland TD, Guszczynski T, Resau JH, Meyerson M.

Mol Cell Biol. 2005 Jan;25(2):612-20.

20.

Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer.

Cho D, Kocher O, Lee JC, Tenen DG, Meyerson ML, Janne PA, Halmos B.

J Clin Oncol. 2005 Jan 1;23(1):235-7. No abstract available. Erratum in: J Clin Oncol. 2005 Apr 1;23(10):2444.

PMID:
15625379

Supplemental Content

Loading ...
Support Center